Enhancing Oxygen,
Fueling Life
Targeting Treatments for Hypoxia
Learn more

Improving Oxygen Availability

Novel Mechanism of Action

Lead drug candidate Trans sodium crocetinate (TSC) enhances the oxygen diffusion process, supporting normal, physiologic levels of oxygen diffusion at uptake and delivery.

Selective for Hypoxic Tissue

In animal models, TSC’s mechanism of action enhanced oxygen availability to hypoxic tissue without oversupplying normoxic tissue.

Demonstrated Safety Profile

TSC has been safe and well tolerated in over 200 subjects dosed in prior preclinical and clinical studies.

OUR TECHNOLOGY

Lead drug
candidate, Trans sodium
crocetinate (TSC)

We are developing our lead product, TSC, to enhance the diffusion of oxygen to tissues with low oxygen levels, also known as hypoxia, a serious complication of many of medicine’s most intractable and difficult-to-treat conditions.

Learn more

News

Latest press releases, announcements, and more.

Diffusion Pharmaceuticals Announces Issuance of U.S. Patent 11,185,523

 Diffusion Pharmaceuticals Announces Issuance of U.S. Patent 11,185,523 2560 1707 Diffusion Pharmaceuticals Inc.

CHARLOTTESVILLE, Va., Dec. 01, 2021 (GLOBE NEWSWIRE) — Diffusion Pharmaceuticals Inc.

Diffusion Pharmaceuticals Doses First Participants in Altitude Trial

 Diffusion Pharmaceuticals Doses First Participants in Altitude Trial 2560 1707 Diffusion Pharmaceuticals Inc.

CHARLOTTESVILLE, Va., Nov. 22, 2021 (GLOBE NEWSWIRE) — Diffusion Pharmaceuticals Inc.

Diffusion Pharmaceuticals Reports Third Quarter Financial Results and Provides Business Update

 Diffusion Pharmaceuticals Reports Third Quarter Financial Results and Provides Business Update 2560 1707 Diffusion Pharmaceuticals Inc.

CHARLOTTESVILLE, Va., Nov. 10, 2021 (GLOBE NEWSWIRE) — Diffusion Pharmaceuticals Inc.

Diffusion Pharmaceuticals to Participate in the Alliance Global Partners Biotech & Specialty Pharma Conference

 Diffusion Pharmaceuticals to Participate in the Alliance Global Partners Biotech & Specialty Pharma Conference 2560 1707 Diffusion Pharmaceuticals Inc.

CHARLOTTESVILLE, Va., Oct. 28, 2021 (GLOBE NEWSWIRE) — Diffusion Pharmaceuticals Inc.

Diffusion Pharmaceuticals Issues Letter to Shareholders

 Diffusion Pharmaceuticals Issues Letter to Shareholders 2560 1707 Diffusion Pharmaceuticals Inc.

CHARLOTTESVILLE, Va., Sept. 09, 2021 (GLOBE NEWSWIRE) — Diffusion Pharmaceuticals Inc.

Diffusion Pharmaceuticals to Present at the 23rd Annual H.C. Wainwright Global Investment Conference

 Diffusion Pharmaceuticals to Present at the 23rd Annual H.C. Wainwright Global Investment Conference 2560 1707 Diffusion Pharmaceuticals Inc.

CHARLOTTESVILLE, Va., Sept. 08, 2021 (GLOBE NEWSWIRE) — Diffusion Pharmaceuticals Inc.

Diffusion Pharmaceuticals Announces Clearance of IND Application for TSC by FDA’s Pulmonology, Allergy, and Critical Care Division

 Diffusion Pharmaceuticals Announces Clearance of IND Application for TSC by FDA’s Pulmonology, Allergy, and Critical Care Division 2560 1707 Diffusion Pharmaceuticals Inc.

CHARLOTTESVILLE, Va., Aug. 30, 2021 (GLOBE NEWSWIRE) — Diffusion Pharmaceuticals Inc.

Diffusion Pharmaceuticals Reports Q2 Financial Results and Provides Business Update

 Diffusion Pharmaceuticals Reports Q2 Financial Results and Provides Business Update 2560 1707 Diffusion Pharmaceuticals Inc.

CHARLOTTESVILLE, Va., Aug. 11, 2021 (GLOBE NEWSWIRE) — Diffusion Pharmaceuticals Inc.

Diffusion Pharmaceuticals Reports Positive Trend in Oxygenation from TCOM Trial

 Diffusion Pharmaceuticals Reports Positive Trend in Oxygenation from TCOM Trial 2560 1707 Diffusion Pharmaceuticals Inc.

CHARLOTTESVILLE, Va., June 30, 2021 (GLOBE NEWSWIRE) — Diffusion Pharmaceuticals Inc.

Diffusion Pharmaceuticals to Webcast Live at Life Sciences Investor Forum

 Diffusion Pharmaceuticals to Webcast Live at Life Sciences Investor Forum 2560 1707 Diffusion Pharmaceuticals Inc.

CHARLOTTESVILLE, Va., June 21, 2021 (GLOBE NEWSWIRE) — Diffusion Pharmaceuticals Inc.

News Releases

Podcasts

Fueling Life, a podcast from Diffusion Pharmaceuticals.

Episode 4: Analyzing TSC’s Impact on Carbon Monoxide Diffusion Through the Lungs
 Episode 4: Analyzing TSC’s Impact on Carbon Monoxide Diffusion Through the Lungs 150 150 Diffusion Pharmaceuticals Inc.

Diffusion’s Chief Medical Officer Dr. Chris Galloway provides an overview of the ILD-DLCO Trial, the third in a trio of Oxygenation Trials that will inform late-phase programs and clinical indications for lead drug candidate TSC.

Episode 3: Evaluating the Effects of TSC on Maximal Oxygen Consumption
 Episode 3: Evaluating the Effects of TSC on Maximal Oxygen Consumption 150 150 Diffusion Pharmaceuticals Inc.

Chief Medical Officer Dr. Chris Galloway previews Diffusion’s Altitude Trial, the second in a trio of Oxygenation Trials that will collectively inform late phase programs and the clinical development plan for lead drug candidate TSC.

Episode 2: Exploring TSC’s Impact on Tissue-Level Changes in Oxygen
 Episode 2: Exploring TSC’s Impact on Tissue-Level Changes in Oxygen 150 150 Diffusion Pharmaceuticals Inc.

Dr. Chris Galloway, Chief Medical Officer of Diffusion, explains the TCOM Trial design, top-line results, and the relevancy of this first of three Oxygenation Trials that together will inform late-phase programs and clinical indications for lead drug candidate TSC.

Episode 1: The Science of Solving for Hypoxia
 Episode 1: The Science of Solving for Hypoxia 150 150 Diffusion Pharmaceuticals Inc.

Diffusion Pharmaceuticals CEO Robert Cobuzzi, Jr., PhD discusses cellular oxygen deficiency, the TSC development plan, and potential future applications for this small molecule therapeutic with a novel MOA.

Introducing Fueling Life: a Podcast from Diffusion Pharmaceuticals
 Introducing Fueling Life: a Podcast from Diffusion Pharmaceuticals 150 150 Diffusion Pharmaceuticals Inc.

This podcast will discuss hypoxia, a potentially fatal shortage of oxygen in a body tissue, and cover the development plan for lead product candidate TSC, which enhances oxygen diffusion to hypoxic tissue.

Listen on Spotify

Back to top